Business
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million
About this update from Atricure, Inc.
[{"type":"text","content":"\n\nWorldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency)\n\n\n\nNet loss of $6.2 million – an improvement of $1.8 million year over year\n\n\n\nAdjusted EBITDA of $15.4 million – an increase of $7.6 million year over year\n\n\n\nGenerated $17.9 million of cash in the quarter\n\n\n\nCompleted enrollment of all 6,500 patients in the ground-breaking LeAAPS trial\n\n\n\n MASON, Ohio--(BUSINESS WIRE)--\nAtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results.\n\n\n“Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. We're seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “With this foundation, we’re excited about the opportunities ahead in the second half of 2025 and beyond to continue delivering strong growth and expanding profitability.”\n\n\nSecond Quarter 2025 Financial Results\n\n\nRevenue for the second quarter 2025 was $136.1 million, an increase of 17.1% over second quarter 2024 revenue (16.5% on a constant currency basis), reflecting continued adoption of our products and therapies globally for the treatment of Afib, LAA management and post-operative pain management. U.S. revenue was $110.6 million, an increase of $15.0 million or 15.7%, compared to the second quarter 2024. U.S. revenue growth was driven by sales across key product lines, including the AtriClip® FLEX·Mini™ device for appendage management, the EnCompass® clamp for open ablation and the cryoSPHERE MAX™ probe for post-operative pain management. International revenue increased $4.8 million or 23.3% (19.9% on a constant currency basis) to $25.6 million, realizing significant growth across all franchises and geographic regions.\n\n\nGross profit for the second quarter 2025 was $101.5 million compared to $86.8 million for the second quarter 2024. Gross margin was 74.5% for the second quarter 2025, a decrease of 15 basis points from the second quarter 2024, ref...